Endocrinology

A recent study from Kaiser Permanente has indicated substantial HbA1c improvements among patients receiving food-based support.

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

If approved, encaleret will be the first treatment specifically indicated for this underrepresented patient population.

FDA accepted Camurus’ resubmitted CAM2029 application for acromegaly, with a target action date of December 18, 2026.

New data from the 45-patient Midpoint Cohort, despite not being powered for statistical significance, indicate a potentially substantial benefit.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

A review of 9 novel drugs approved by the US Food and Drug Administration during the second quarter of 2026.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

A review of 22 novel drugs approved by the US Food and Drug Administration during the first half of 2026, with links to coverage from MJH Life Sciences publications.

Catch up on major trial results, groundbreaking FDA decisions, and key clinician insights from major endocrinology conferences.

Ersodetug Shows Hypoglycemia Reduction Trends, Target Engagement in Phase 3 cHI Trial

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover recent data released by Eledon regarding tegoprubart for type 1 diabetes.

The FDA has approved veligrotug-vvze for thyroid eye disease regardless of activity or duration.

Ersodetug showed target engagement and hypoglycemia reduction trends in phase 3 cHI study but missed primary endpoints in SunRIZE trial.

Igudesman highlights satiety, diet quality, and macronutrients, among other endpoints, as important additional methods beyond weight loss for managing T1D.

Real-world data highlight GLP-1 receptor agonist use with metreleptin in lipodystrophy and clinician guidance on timing and safety monitoring.

Lindsay Fourman, MD, discusses early real-world data exploring the use of GLP-1 receptor agonists alongside metreleptin in lipodystrophy.

Igudesman discusses her presentation at ENDO 2026, during which she covered the importance of managing obesity with lifestyle changes in patients with T1D.

Rishi Wadhera, MD, MPP, MPhil, addresses performance metrics, cross-specialty prescribing, and the policy forces reshaping the cardiometabolic care cascade.

Rishi Wadhera, MD, MPP, MPhil, discusses where the cardiometabolic care cascade is failing most consequentially at the 10th Annual Heart in Diabetes Meeting.

First placebo-controlled phase 3 METRE-PL data show prevalent metabolic burden in familial partial lipodystrophy (FPLD) despite standard therapy.

Corxel reported CX11 met phase 2 endpoints in adults with obesity or overweight, with up to 11.5% weight loss at 36 weeks.

In the final segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

In the fourth segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

In the third segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.